International Journal of Molecular Sciences · 2024 · 12 citations · 81 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyMolecular OncologyCancer BiomarkersCancer ImmunotherapyCheckpoint Inhibitor TherapyImmuno-oncology BiomarkersLung CancerMicrorna BiologyHost-microbiome Interactions In CancerImmune Checkpoint Inhibitor BiomarkersLung MicrobiomeMicrorna In CancerMicrorna Prognostic MarkersNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment
Lung cancer (LC) is one of the most prevalent cancers in both men and women and today is still characterized by high mortality and lethality. Several biomarkers have been identified for evaluating the prognosis of non-small cell lung cancer (NSCLC) patients and selecting the most effective therapeutic strategy for these patients. The introduction of innovative targeted therapies and immunotherapy with immune checkpoint inhibitors (ICIs) for the treatment of NSCLC both in advanced stages and, more recently, also in early stages, has revolutionized and significantly improved the therapeutic scenario for these patients. Promising evidence has also been shown by analyzing both micro-RNAs (miRNAs) and the lung/gut microbiota. MiRNAs belong to the large family of non-coding RNAs and play a role in the modulation of several key mechanisms in cells such as proliferation, differentiation, inflammation, and apoptosis. On the other hand, the microbiota (a group of several microorganisms found in human orgasms such as the gut and lungs and mainly composed by bacteria) plays a key role in the modulation of inflammation and, in particular, in the immune response. Some data have shown that the microbiota and the related microbiome can modulate miRNAs expression and vice versa by regulating several intracellular signaling pathways that are known to play a role in the pathogenesis of lung cancer. This evidence suggests that this axis is key to predicting the prognosis and effectiveness of ICIs in NSCLC treatment and could represent a new target in the treatment of NSCLC. In this review, we highlight the most recent evidence and data regarding the role of both miRNAs and the lung/gut microbiome in the prediction of prognosis and response to ICI treatment, focusing on the link between miRNAs and the microbiome. A new potential interaction based on the underlying modulated intracellular signaling pathways is also shown.
81
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017 · 5.4K citations
Life Sciences, Immunology, Oncology +17
The impact of microRNAs on protein output
Daehyun Baek, Judit Villén, Chanseok Shin et al. · Nature · 2008 · 3.6K citations · Full text
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Ta-Chung Yu, Fangfang Guo, Yanan Yu et al. · Cell · 2017 · 2.2K citations · Full text
Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 Responses
Li‐Fan Lu, Mark Boldin, Ashutosh Chaudhry et al. · Cell · 2010 · 1K citations · Full text